[PDF] Top 20 Repurposing Dichloroacetate for the Treatment of Multiple Myeloma

... DCA treatment, but PDK3 siRNA knockdown led to considerably increased sensitivity to DCA ...DCA treatment (Figure ...DCA treatment is displayed in Table ... See full document

... the treatment of multiple myeloma, it remains an incurable disease, with relapses and resistances frequently ...important treatment options in anticancer ...on myeloma cells and, to a ... See full document

... Multiple myeloma is a bone marrow malignancy characterised by clonal proliferation of neoplastic plasma cells, monoclonal protein in the blood or urine and organ dysfunction (Palumbo ...with myeloma ... See full document

... Abstract: Multiple myeloma is the second most common hematologic malignancy in the ...for multiple myeloma, new options for treatment in the relapsed setting are on the ...the ... See full document

... Multiple myeloma (MM) is a B cell malignancy characterized by excess monotypic plasma cells in the BM in association with monoclonal protein in serum and/or urine, decreased normal immunoglobulin (Ig) ... See full document

... Multiple myeloma management has undergone profound changes in the past thanks to advances in our understand- ing of the disease biology and improvements in treatment and supportive care ...European ... See full document

... Multiple myeloma is a mature B-cell neoplasm charac- terized by a monoclonal expansion of plasma cells in the bone marrow often accompanied by hemocytopenias, immunodeficiency, osteolytic lesions, ... See full document

... of multiple myeloma (MM) therapy has changed dramatically in the past two ...MM treatment outcomes ...oma treatment, efficacious monoclonal antibodies have been long awaited in ...the ... See full document

... Abstract: Carfilzomib is a second-generation proteasome inhibitor with well-documented clinical activity as a single agent in patients with relapsed/refractory multiple myeloma. Carfilzomib can partially ... See full document

... the treatment of multiple myeloma (MM) - from immunomodulating agents to proteasome inhibitors to histone deacetylase (HDAC) inhibitors and, most recently, monoclonal ... See full document

... biologically-based treatment in various perspec- tives, targeting not only the malignant cells, but also its ...Target treatment might be less toxic than conventional chemotherapy. In multiple ... See full document

... Abstract: Multiple myeloma (MM) is a clonal malignancy of plasma cells that is newly diag- nosed in ~30,000 patients in the US each ...novel treatment option for ... See full document

... in myeloma initiation and ...the treatment of multiple myeloma fol- lowing at least two prior lines of ...RR multiple myeloma, panobinostat in combination with steroids and a ... See full document

... in multiple myeloma (MM) therapy with the introduction of several small molecules, mostly orally effective, whose mechanisms are based on proteasome inhibition, histone deacetylase (HDAC) blockade, and ... See full document

... Multiple myeloma (MM) is a relatively frequent hematological neoplasm that is characterized by bone marrow (BM) infiltration by malignant plasma cells secreting a monoclonal component in the serum or ... See full document

... elderly multiple myeloma, ...personalized treatment approaches, based on patient comorbidities, as the three novel agents have somewhat different toxicity profi ...maintenance treatment needs ... See full document

... in multiple myeloma (MM), many patients still eventually ...in myeloma cells at the gene and protein level, but not expressed in other tissues, including hematopoietic stem cells, making CS1 a ... See full document

... relapsed myeloma setting, its use quickly spread to the newly diag- nosed transplant-eligible and transplant-ineligible setting, and it is now considered an important backbone therapy for all stages of the ...the ... See full document

... As stated before, CRBN protein has been identified as the pharmacological target for thalidomide and its analogs, and there is a clear relationship between low CRBN expres- sion and the resistance to these drugs in ... See full document

... later treatment cycles following achievement of best ...of treatment discontinu- ation due to adverse events (AEs) or to disease progression was 15% and 7% in the VMP arm and 14% and 22% in the MP arm, ... See full document